Climb Bio, Inc. (CLYM)
CLYM moved a median of +0.26% 30 minutes after news, and +0.69% by the close. How CLYM actually reacts to news — the realized, point-in-time move the market made, measured across 138 labeled events over the last three years with zero look-ahead.
CLYM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.04% | 51% | 137 |
| 30-min | +0.26% | 53% | 138 |
| 60-min | -0.65% | 44% | 138 |
| to close | +0.69% | 55% | 134 |
| Middle 50% of CLYM reactions | -2.43% to +2.55% |
|---|---|
| Median reaction (30-min) | +0.26% |
| Measured reactions | 138 |
Half of all Climb Bio, Inc. news events land between -2.43% and +2.55% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CLYM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | +0.57% | 69% | -0.71% |
| Coverage initiations | 41 | -0.82% | 46% | -0.84% |
| Rating reiterations | 39 | 0.00% | 49% | -0.42% |
| Price-target raises | 11 | +0.23% | 55% | -1.56% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how CLYM ranks against every other measured name →
That’s how CLYM usually reacts — get an email when it moves on news →Email me when CLYM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CLYM's baseline. Nothing else.
Recent CLYM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug | Press release | GlobeNewswire | -1.96% | -2.58% | |
| Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy | Press release | GlobeNewswire | +4.73% | +4.51% | |
| Form 8-K Climb Bio, Inc. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | +4.73% | +4.51% | |
| Climb Bio to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +2.10% | +1.76% | |
| Form 8-K Climb Bio, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | +12.16% | |
| Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +1.29% | +12.54% | |
| Form 10-Q Climb Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.29% | +12.54% | |
| Form 8-K Climb Bio, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | +12.54% | |
| Form 8-K Climb Bio, Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -0.53% | -2.94% | |
| Form 8-K Climb Bio, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | -1.46% | |
| Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 | Press release | GlobeNewswire | -0.09% | +1.77% | |
| Form 8-K Climb Bio, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | +1.77% | |
| Form EFFECT Climb Bio, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.90% | -2.35% | |
| Form 8-K Climb Bio, Inc. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +1.72% | +3.29% | |
| Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development | Press release | GlobeNewswire | +1.67% | -2.04% | |
| Form 8-K Climb Bio, Inc. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +1.67% | -2.04% | |
| Form S-3 Climb Bio, Inc. | SEC filing · Form S-3 | SEC EDGAR | +2.82% | +8.96% | |
| Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 | Press release | GlobeNewswire | +2.55% | +1.79% | |
| Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress | Press release | GlobeNewswire | -1.79% | -3.33% | |
| Climb Bio to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -2.05% | -0.45% | |
| Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -1.76% | -4.57% | |
| Form 10-Q Climb Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.76% | -4.57% | |
| Form 8-K Climb Bio, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -1.76% | -4.57% | |
| Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts | Press release | GlobeNewswire | +11.78% | +15.31% | |
| Form 8-K Climb Bio, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +11.78% | +15.31% | |
| Form D Climb Bio, Inc. | SEC filing · Form D | SEC EDGAR | +11.78% | +15.31% | |
| Climb Bio, Inc. Announces $110.0 Million Private Placement | Press release | GlobeNewswire | -2.22% | -6.56% | |
| Form 8-K Climb Bio, Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -2.22% | -6.56% | |
| Form ARS Climb Bio, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.77% | +4.05% | |
| Form DEF 14A Climb Bio, Inc. For: Jun 05 | SEC filing · Form DEF | SEC EDGAR | +0.77% | +4.05% | |
| Form DEFA14A Climb Bio, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.77% | +4.05% | |
| Form PRE 14A Climb Bio, Inc. For: Jun 05 | SEC filing · Form PRE | SEC EDGAR | +0.54% | +3.35% | |
| Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 | Press release | GlobeNewswire | -1.65% | +0.00% | |
| Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy | Press release | GlobeNewswire | -1.51% | +4.09% | |
| Form 8-K Climb Bio, Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -0.15% | +2.43% | |
| Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -1.92% | +1.51% | |
| Form 10-K Climb Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.92% | +1.51% | |
| Form 8-K Climb Bio, Inc. For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -1.92% | +1.51% | |
| Form S-8 Climb Bio, Inc. | SEC filing · Form S-8 | SEC EDGAR | -1.92% | +1.51% | |
| Climb Bio to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +3.89% | -4.71% | |
| Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 | Press release | GlobeNewswire | +10.02% | +6.76% | |
| Form 8-K Climb Bio, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +10.02% | +6.76% | |
| Form 8-K Climb Bio, Inc. For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | -3.90% | -8.54% | |
| Form 8-K Climb Bio, Inc. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +1.93% | +11.11% | |
| Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.57% | +2.86% | |
| Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +1.07% | +4.28% | |
| Form 10-Q Climb Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.07% | +4.28% | |
| Form 8-K Climb Bio, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | +4.28% | |
| Climb Bio to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.49% | -2.44% | |
| Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy | Press release | GlobeNewswire | -2.59% | -2.59% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CLYM section they belong to.
Where else CLYM is measured.
CLYM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Climb Bio, Inc.'s median reaction calculated?
Every labeled CLYM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 138 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of CLYM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CLYM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.